Mathematically mapping the network of cells in the tumor microenvironment

Mike van Santvoort^{1,2,5}, Óscar Lapuente-Santana², Francesca Finotello^{3,4}, Pim van der Hoorn^{1,5} and Federica Eduati^{2,5}

m.v.santvoort@tue.nl o.lapuente.santana@tue.nl

w.l.f.v.d.hoorn@tue.nl f.eduati@tue.nl

Anti-tumor immune microenvironmen

¹ Department of Mathematics and Computer Science, Eindhoven University of Technology, The Netherlands
 ² Department of Biomedical Engineering, Eindhoven University of Technology, The Netherlands
 ³ Institute of Molecular Biology, University of Innsbruck, Austria


⁴ Digital Science Center (DiSC), University of Innsbruck, Austria
 ⁵ Institute for Complex Molecular Systems, Eindhoven University of Technology, The Netherlands

Tumors as communication networks

- The interaction of all cells/proteins inside the TME determine how a tumor develops (Figure 1).
- Reconstructing the cell-cell interaction network informs on TME functioning and potential therapeutic intervention (e.g. immunotherapy¹).
- Single-cell RNA sequencing (scRNA-seq) can characterize elements in the TME, but has limited clinical applications.²
- Building cell-cell interaction networks from increasingly available bulk RNA sequencing (RNA-seq) can allow characterization at the individual patient level.³

Aim:

- 1. Create a model (called RaCInG) to reconstruct cell-cell interaction networks in the TME using bulk RNA-seq data.
- 2. Use the model to quantify important features of a patient's TME.



Statistical

Analysis


Patients

Group




Cell-type and ligandreceptor pair quantifications using **bulk RNA-seq**.


Cell-ligand and cellreceptor compatibility matrices based on cell-type specific gene expression data.








Extracted features



Features: Count how often given cell-types communicate directly, through wedges, and through triangles.

Immune suppressive microenvironmer


Figure 1: All facets of the TME contribute to cancer malignancy.⁴



Cell types used Tumor cells, immune cells, endothelial cells, **in features:** CAFs.

Protein info: Information about ligands and receptors retrievable.

Case study: TME and immune subtypes in skin cutaneous melanoma (SKCM)



Tr_CD8_CD8_Tumor 🛑 Tr_CD8_CD8_M 🔴 W_CD8_CD8_CD8 🔴 W_CD8_CD8_Tumor 🔴 Tr_B_CD8_CD8 📥 W_CD8_CD8_M 🔴 Tr_CD8_M_M 🔴 Tr_CD8_CD8_Treg 📥 Tr_B_B_CD8 📥 Tr_Treg_Treg_Treg 🔺 Tr_Treg_Treg_Tumor 👍 Tr_B_B_Treg 👍 Tr_B_Treg_Treg 👍 W_DC_DC_DC -Tr_B_CD8_Treg 🤺 W_DC_Tumor_M SKCM Cancer Types

Figure 2: Comparison of immune enriched (IE) and fibrotic (F) patients⁵ from TCGA⁶ SKCM dataset. Top 20 features with lowest p-value (Wilcoxon rank sum test) are highlighted.

batients⁵ from TCGA⁶ SKCM Figure 3: Features comparing SKCM and STAD with other TCGA cancer types. Feature is m test) are highlighted. chosen when its deviates the most from the same feature in pan-cancer analysis.

Tr_CD8_CD8_CD8 📥

Observations:

- More CD8+ T-cell and Treg-cell communication with tumor cells in IE group.⁵
- More CAF communication with tumor and endothelial cells in the F group.⁷
- Macrophage regulation by CAFs and endothelial cells in F group.⁸

Conclusion:

- TME reconstruction with RaCInG can highlight detailed properties that contribute to patient grouping.
- These features go beyond what can be directly inferred from (bulk) transcriptomics and cellular deconvolution.
- Methodology blocks can be adjusted to fit research needs.

Case study: Network communication and

B

Responders





response to immunotherapy in melanoma

Observations:

- Increased CD8+ T-cell activity in responders due to blockage of PD-L1: self-activation and greater cytotoxicity.⁹
- More macrophage communication with tumors in the nonresponder group: new mechanisms of immune evasion exploited.¹⁰

Conclusion:

TME reconstruction with RaCInG can reveal TME features explaining/predicting patient response to ICB therapy.





Figure 4: Quantification of average communication level between pairs of cells for patients in different response groups after being put on anti PD-L1 therapy. Data from Gide¹¹ and Aulander¹² used.



References

1. Smyth et al., Nat Rev Clin Oncol., 2016

- 2. Armingol et al., Nat Rev Genetics, 2021
- 3. Wang, Patkar et al., Cancer Discov., 2022
- 4. Anderson and Simon, Current Biology, 2020
- 5. Bagaev et al., Cancer Cell, 2021
- Weinstein et al., Nat Genetics, 2013
 Papaccio et al., Int J Mol Sci, 2021
 Pieniazek et al., Oncol Lett, 2018
 Weigelin, B. et al., Nat. Com., 2021

10. Mukaida, N. et al., Tumor microenv. 2020

Gide, T.N. et al., Cancer Cell 2019
 Auslander, N. et al., Nat. Med. 2018

